NVCT
NASDAQNuvectis Pharma Inc.
Price$9.52+0.01 (+0.16%)
02:45 PM07:45 PM
News · 26 weeks17-80%
2025-12-072026-05-31
Mix790d
- SEC Filings4(57%)
- Other3(43%)
Latest news
25 items- PRNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQFort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York. Conference Details: Date: Tuesday, May 19, 2026Company Presentation: 9:00 – 9:30AM EDTPresenter: Ron Bentsur, Chairman and Chief Executive Officer of NuvectisWebcast Link: hereLocation: New York, NY A webcast of the presentation will be avai
- SECSEC Form 10-Q filed by Nuvectis Pharma Inc.10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsNXP900 Phase 1b clinical program continues to enroll patients at select sites in the USNXP900 preclinical presentations at the 2026 American Association for Cancer Research ("AACR") Annual Meeting" further support the clinical development strategy FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Ex
- SECSEC Form DEFA14A filed by Nuvectis Pharma Inc.DEFA14A - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form DEF 14A filed by Nuvectis Pharma Inc.DEF 14A - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingFort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2026 American Association for Cancer Research Meeting (2026 AACR), taking place from April 17th to April 22nd in San Diego, CA. Abstract TitlePoster Presentation DetailsNXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC modelsSession TitleCombina
- SECSEC Form EFFECT filed by Nuvectis Pharma Inc.EFFECT - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form S-3 filed by Nuvectis Pharma Inc.S-3 - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form 10-K filed by Nuvectis Pharma Inc.10-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. Reports 2025 Financial Results and Business HighlightsFORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026. Our Phase 1b monotherapy s
- INSIDERChief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 9% to 1,793,068 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERChairman & CEO Bentsur Ron was granted 150,000 shares, increasing direct ownership by 4% to 3,675,924 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERChief Science & Business Off Poradosu Enrique was granted 150,000 shares, increasing direct ownership by 9% to 1,806,319 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERVice President, Finance Carson Michael J. was granted 61,200 shares, increasing direct ownership by 44% to 200,118 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- PRNuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLCFort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib is Tagrisso®, marketed by Astra Zeneca. Tagrisso, a 3rd generation EGFR inhibitor is broadly used in patients with NSCLCmut+ as single agent or in combination with chemotherapy a
- PRNuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company")), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell lung cancer. To register for the event, click here. The event will feature Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Asier Unc
- INSIDERChairman & CEO Bentsur Ron bought $28,600 worth of shares (5,000 units at $5.72), increasing direct ownership by 0.14% to 3,525,924 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Sanchez Juan bought $75,270 worth of shares (13,000 units at $5.79), increasing direct ownership by 20% to 78,150 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Kaplan Matthew L. bought $64,240 worth of shares (11,000 units at $5.84), increasing direct ownership by 10% to 124,760 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRCORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsFORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ:NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dos
- SECSEC Form 10-Q filed by Nuvectis Pharma Inc.10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsNXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosingNXP900 clinical drug-drug interaction study in healthy volunteers successfully completed supporting our strategy for combination therapyPoster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics high
NVCT FAQ
7 questionsWhat does Nuvectis Pharma Inc. do?
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.Where does NVCT stock trade?
Nuvectis Pharma Inc. (NVCT) is listed on NASDAQ.What sector and industry is NVCT in?
Nuvectis Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nuvectis Pharma Inc. go public?
Nuvectis Pharma Inc. (NVCT) completed its IPO in 2022.What are analysts saying about NVCT?
Nuvectis Pharma Inc. has had 4 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $1700.00 price target on 2025-04-02. Recent price targets range from $1400.00 to $2100.00.What companies are similar to NVCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NVCT side-by-side with any of them on Quantisnow.How can I track NVCT on Quantisnow?
Quantisnow aggregates Nuvectis Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVCT to receive live email and push alerts on every new disclosure.